Summary: Researchers have determined the molecular structure of the amyloid nucleus—the initial, rate-limiting assembly that triggers amyloid formation in neurodegenerative diseases such as Huntington’s.
This discovery points to a new therapeutic strategy: prevent the very first nucleation event. The team found that the nucleus forms within a single protein molecule and that blocking this formation could halt the cascade that leads to toxic amyloid accumulation and neuronal death.
If validated in further studies, this approach could change how we treat Huntington’s disease and many other amyloid-associated disorders.
Key Facts:
- The pathogenic amyloid assembly starts with a nucleus that can form inside a single protein molecule.
- The study used Distributed Amphifluoric Förster Resonance Energy Transfer (DAmFRET), a method that reveals protein self-assembly inside living cells.
- The research identifies a critical threshold of 36 consecutive glutamine residues (Qs) in the protein sequence as the point where nucleation becomes likely, offering a precise target for intervention.
Source: Stowers Institute for Medical Research
Background
Neurodegenerative disorders such as Huntington’s, Alzheimer’s, and Parkinson’s are linked to amyloid deposits—aggregates of misfolded proteins in the brain. Although decades of research have explored how amyloids form and why they are toxic, the molecular details of the initiating event, or nucleation, have remained unclear. That gap has limited efforts to develop treatments that stop disease progression at its earliest stage.
Researchers at the Stowers Institute for Medical Research now report the first experimental characterization of a polyglutamine (polyQ) amyloid nucleus—the critical early structure that seeds aggregation in Huntington’s disease. Published in eLife on June 13, 2023, the study led by Associate Investigator Randal Halfmann, Ph.D., proposes that preventing this initial nucleation could be a powerful and general approach to treating polyQ and other amyloid-related diseases.
“This is the first time anyone has experimentally determined the structure of an amyloid nucleus, despite the central role amyloids play in major neurodegenerative diseases,” said Halfmann. The finding helps explain a long-standing mystery: why disease correlates with amyloid presence even when those deposits themselves are not always the direct toxic agents.
Co-first authors Tej Kandola, Ph.D., and Shriram Venkatesan, Ph.D., traced the nucleus to the huntingtin protein and showed that the nucleation occurs within a single molecule rather than requiring multiple proteins to come together first.
Proteins are built from 20 amino acids, and some disease-causing proteins contain long repeats of the amino acid glutamine (Q). Huntington’s and related “polyQ” disorders arise when these glutamine repeats exceed a certain length, causing the protein to adopt a conformation that initiates a harmful aggregation cascade.
For decades, researchers observed that disease risk rises when huntingtin contains roughly 36 or more consecutive Qs, but the structural explanation was missing. This study identifies the minimal structural unit that nucleates amyloid formation: a compact bundle formed from patterned segments of three glutamines repeated in particular positions, creating a four-stranded steric zipper. That microscopic crystal can form inside a single protein molecule and then trigger the polymerization process that leads to pathology.
“We’ve now visualized the first link in the chain and discovered a new way to stop it,” Halfmann said. The team’s data indicate that artificially promoting harmless preemptive oligomerization of the proteins—bringing them together in non-amyloid configurations—can block nucleation, offering a novel therapeutic route to test in animal models and brain organoids.
Methodological advance
A crucial element of the work was DAmFRET, a technique developed in the Halfmann lab that monitors protein self-association inside single living cells. By minimizing the effective reaction volume, the researchers could observe the stochastic nucleation events and systematically manipulate sequence patterns to discover which features control nucleation frequency.
Combining intracellular measurements with molecular simulations, the team showed the patterned three-glutamine segments encode the steric zipper. They also demonstrated that the formed zipper “self-poisons” growth by misorienting incoming polypeptides on orthogonal faces—behavior characteristic of polymer crystals with intramolecular nuclei. Importantly, forcing proteins into benign oligomers before nucleation occurs prevented amyloid formation in their assays.
These insights not only clarify the molecular etiology of polyQ diseases but also provide a concrete molecular model for studying amyloid nucleation more broadly. Because amyloid formation correlates with aging, the approach could ultimately reveal mechanisms that link protein aggregation and age-related decline. A preventative strategy that delays or eliminates nucleation offers renewed hope for patients carrying pathogenic polyQ proteins.
“The emerging paradigm is that everything follows from a single spontaneous change in protein shape,” Halfmann said. “That event ignites the chain reaction for amyloids that kill cells and may reveal how amyloids cause disease.”
Additional contributors to the study include Jiahui Zhang, Ph.D., Brooklyn Lerbakken, Alex Von Schulze, Ph.D., Jillian F. Blanck, Jianzheng Wu, Ph.D., Jay Unruh, Ph.D., Paula Berry, Jeffery Lange, Ph.D., Andrew Box, Malcolm Cook, and Celeste Sagui, Ph.D.
Funding: This research was supported by the National Institute of General Medical Sciences of the NIH (award R01GM130927) and institutional support from the Stowers Institute for Medical Research. The authors are solely responsible for the content and conclusions reported.
About this Huntington’s disease research news
Author: Joe Chiodo
Source: Stowers Institute for Medical Research
Contact: Joe Chiodo – Stowers Institute for Medical Research
Image: The image is credited to Neuroscience News
Original Research: Open access. “Pathologic polyglutamine aggregation begins with a self-poisoning polymer crystal” by Tej Kandola et al., eLife.
Abstract
Pathologic polyglutamine aggregation begins with a self-poisoning polymer crystal
A major goal in amyloid research has been to reveal the structural basis of the rate-limiting nucleating event that initiates aggregation. Because nucleation is transient and stochastic, it has been difficult to capture with traditional biochemical, structural, or computational approaches.
Focusing on polyglutamine (polyQ)—the sequence motif whose expansion causes Huntington’s and related neurodegenerative diseases—the authors used an intracellular reporter of self-association to measure nucleation frequencies as a function of concentration, conformational templates, and rational sequence permutations. Their results show that pathological polyQ nucleation depends on repeated segments of three glutamines at alternating positions. Molecular simulations indicate these segments form a four-stranded steric zipper with interdigitated Q side chains. Once the zipper forms, it impairs its own linear growth by engaging incoming polypeptides on orthogonal faces, a behavior reminiscent of polymer crystals with intramolecular nuclei. The authors further show that preemptive oligomerization of polyQ can block amyloid nucleation. By defining the physical nature of the rate-limiting event for polyQ aggregation in cells, this work clarifies the molecular basis of polyQ diseases.